ATE224184T1 - Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe - Google Patents
Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffeInfo
- Publication number
- ATE224184T1 ATE224184T1 AT94930794T AT94930794T ATE224184T1 AT E224184 T1 ATE224184 T1 AT E224184T1 AT 94930794 T AT94930794 T AT 94930794T AT 94930794 T AT94930794 T AT 94930794T AT E224184 T1 ATE224184 T1 AT E224184T1
- Authority
- AT
- Austria
- Prior art keywords
- vaccines
- compositions
- antigens
- microspheres
- microencapsulating antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14179693A | 1993-10-22 | 1993-10-22 | |
US14355593A | 1993-10-25 | 1993-10-25 | |
PCT/US1994/011753 WO1995011010A1 (en) | 1993-10-22 | 1994-10-13 | Methods and compositions for microencapsulation of antigens for use as vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE224184T1 true ATE224184T1 (de) | 2002-10-15 |
Family
ID=26839455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94930794T ATE224184T1 (de) | 1993-10-22 | 1994-10-13 | Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0724432B1 (de) |
JP (1) | JPH09504027A (de) |
AT (1) | ATE224184T1 (de) |
AU (1) | AU7980794A (de) |
CA (1) | CA2172509C (de) |
DE (1) | DE69431404T2 (de) |
DK (1) | DK0724432T3 (de) |
ES (1) | ES2184769T3 (de) |
WO (1) | WO1995011010A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE40786E1 (en) * | 1984-03-16 | 2009-06-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US6514533B1 (en) | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
RU2143889C1 (ru) * | 1993-02-23 | 2000-01-10 | Генентек, Инк. | Способ стабилизации полипептида, способы получения композиций полипептида и композиции |
JP3841309B2 (ja) * | 1993-10-22 | 2006-11-01 | ジェネンテック・インコーポレーテッド | 流動床乾燥工程を含んでなるミクロスフェアの製造方法 |
GB9514285D0 (en) * | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
GB2317340B (en) * | 1995-07-13 | 1998-12-23 | Danbiosyst Uk | Polymeric lamellar substrate particles for drug delivery |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
CA2230494A1 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
GB9709900D0 (en) * | 1997-05-15 | 1997-07-09 | Microbiological Res Authority | Microencapsulated DNA for vaccination and gene therapy |
EP1579851A3 (de) * | 1997-08-29 | 2009-09-02 | Corixa Corporation | Schnellfreisetzende enkapsulierte bioaktive Wirkstoffe zur Induzierung oder Erhöhung einer immunantwort und Verwendung derselben |
WO1999009956A1 (en) * | 1997-08-29 | 1999-03-04 | Corixa Corporation | Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof |
US6086901A (en) * | 1997-12-16 | 2000-07-11 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
US7393630B2 (en) | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
CN1242750C (zh) * | 2000-02-08 | 2006-02-22 | 分子农业生物学院 | 可生物降解的且生物相容的封装有肠炎沙门氏菌的聚合物微球体 |
ES2160089B1 (es) * | 2000-03-15 | 2002-05-16 | Inst Cientifico Tecnol Navarra | Procedimiento y aparato para la produccion de microparticulas para la liberacion controlada de farmacos hidrosolubles y vectores virales. aplicacion a la adiministracion de adn plasmidico y de adenovirus recombinantes defectivos. |
US6565888B1 (en) * | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
EP1417236A4 (de) * | 2001-07-10 | 2010-03-17 | Corixa Corp | Zusammensetzungen und verfahren zur abgabe von proteinen und adjuvantien in einer mikrokügelchen-kapsel |
PL376476A1 (en) | 2002-10-24 | 2005-12-27 | Merz Pharma Gmbh & Co.Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
KR20060030469A (ko) | 2003-05-27 | 2006-04-10 | 포레스트 래보러토리즈, 인코포레이티드 | 우울증 및 그 밖의 기분장애의 치료를 위한 nmda수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물 |
US20050260217A1 (en) * | 2004-03-04 | 2005-11-24 | Corixa Corporation | Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof |
CN100342916C (zh) * | 2004-12-08 | 2007-10-17 | 上海第二医科大学附属第九人民医院 | 一种可生物降解医用材料标记物及其制备 |
CN101437539B (zh) | 2005-07-05 | 2013-10-02 | 康奈尔研究基金会(有限公司) | 通过干扰cd99l2阻断白细胞迁出和炎症 |
KR20080047395A (ko) | 2005-08-25 | 2008-05-28 | 다이호야쿠힌고교 가부시키가이샤 | T세포 인식 에피토프 펩티드를 고정화 또는 내포화한생분해성 나노입자 |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
US8877814B2 (en) | 2007-09-12 | 2014-11-04 | Merz Pharma Gmbh & Co. Kgaa | Titration package for neramexane and its use in the treatment of an inner ear disorder |
ES2358703B1 (es) * | 2007-11-14 | 2012-03-21 | Universidad Del Pais Vasco | Empleo de micropart�?culas para su uso como vacunas y la liberación de moléculas biológicamente activas. |
ES2327375B1 (es) | 2007-11-14 | 2010-08-05 | Universidad Del Pais Vasco | Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas. |
EP2085120A1 (de) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Verwendung von Substanzen zur Behandlung zentraler und peripherer Insulinrezeptorbeeinträchtigung oder Insulinresistenz |
EP2318832B1 (de) | 2008-07-15 | 2013-10-09 | Academia Sinica | Glycan-arrays auf objektträgern mit ptfe-aluminiumbeschichtung und entsprechende verfahren |
TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類 |
US8399519B2 (en) | 2008-12-19 | 2013-03-19 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
US20120136005A1 (en) | 2009-06-30 | 2012-05-31 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of anxiety |
WO2011000564A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of drug addiction |
WO2011000562A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of certain movement disorders |
US20120190690A1 (en) | 2009-06-30 | 2012-07-26 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of weight disorders |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US20110294890A1 (en) | 2010-05-28 | 2011-12-01 | Merz Pharma Gmbh & Co. Kgaa | Neramexane for the treatment or prevention of inner ear disorders |
WO2012023033A2 (en) | 2010-08-18 | 2012-02-23 | Purdue Pharma L.P. | Improved peptide immunogens |
WO2012098000A1 (en) | 2011-01-20 | 2012-07-26 | Merz Pharma Gmbh & Co. Kgaa | Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss |
WO2012171653A1 (en) | 2011-06-15 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Sarizotan for use in the treatment of attention deficit hyperactivity disorder (adhd) |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
TW201412325A (zh) | 2012-06-20 | 2014-04-01 | 梅茲製藥有限兩合公司 | 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療 |
US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
CN104869981B (zh) * | 2012-11-09 | 2018-05-08 | 赢创有限公司 | 用于协调微粒性质的干燥方法 |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
US10300136B2 (en) * | 2013-12-16 | 2019-05-28 | Massachusetts Institute Of Technology | Micromolded or 3-D printed pulsatile release vaccine formulations |
WO2015095185A1 (en) | 2013-12-16 | 2015-06-25 | Massachusetts Institute Of Technology | Fortified micronutrient salt formulations |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
EP3129767B1 (de) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reaktive markierungsverbindungen und ihre verwendungen |
KR20170005142A (ko) | 2014-05-27 | 2017-01-11 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
EP3149036A4 (de) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20-glycoantikörper und verwendungen davon |
EP3149037A4 (de) | 2014-05-27 | 2018-01-10 | Academia Sinica | Anti-her2-glykoantikörper und verwendungen davon |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗TNFα糖操作抗体群およびその使用 |
US9439864B2 (en) * | 2014-07-07 | 2016-09-13 | Antriabio, Inc. | Solvent extraction from biodegradable microparticles |
TWI745275B (zh) | 2014-09-08 | 2021-11-11 | 中央研究院 | 使用醣脂激活人類iNKT細胞 |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
CN108350605A (zh) | 2015-09-04 | 2018-07-31 | 台湾浩鼎生技股份有限公司 | 聚糖阵列以及使用方法 |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
AU2017239637A1 (en) | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
BR112018071683A2 (pt) | 2016-04-22 | 2019-02-19 | Obi Pharma, Inc. | método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente |
WO2018013797A1 (en) | 2016-07-13 | 2018-01-18 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
WO2018022933A1 (en) | 2016-07-27 | 2018-02-01 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
US11643456B2 (en) | 2016-07-29 | 2023-05-09 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
TW202035444A (zh) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
EP3791873A1 (de) | 2019-09-16 | 2021-03-17 | Universite De Bordeaux | Verfahren zur behandlung und/oder vorbeugung von erkrankungen und symptomen im zusammenhang mit bkca- und/oder sk-kanalophathien |
AU2022226584A1 (en) | 2021-02-24 | 2023-08-17 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
DE3855869T2 (de) * | 1987-02-20 | 1997-10-02 | Genentech Inc | Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern |
US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
JP2653255B2 (ja) * | 1990-02-13 | 1997-09-17 | 武田薬品工業株式会社 | 長期徐放型マイクロカプセル |
-
1994
- 1994-10-13 DK DK94930794T patent/DK0724432T3/da active
- 1994-10-13 WO PCT/US1994/011753 patent/WO1995011010A1/en active IP Right Grant
- 1994-10-13 CA CA2172509A patent/CA2172509C/en not_active Expired - Lifetime
- 1994-10-13 AU AU79807/94A patent/AU7980794A/en not_active Abandoned
- 1994-10-13 ES ES94930794T patent/ES2184769T3/es not_active Expired - Lifetime
- 1994-10-13 EP EP94930794A patent/EP0724432B1/de not_active Expired - Lifetime
- 1994-10-13 AT AT94930794T patent/ATE224184T1/de active
- 1994-10-13 DE DE69431404T patent/DE69431404T2/de not_active Expired - Lifetime
- 1994-10-13 JP JP7512118A patent/JPH09504027A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2172509A1 (en) | 1995-04-27 |
DE69431404D1 (de) | 2002-10-24 |
EP0724432A1 (de) | 1996-08-07 |
AU7980794A (en) | 1995-05-08 |
JPH09504027A (ja) | 1997-04-22 |
DK0724432T3 (da) | 2003-01-27 |
CA2172509C (en) | 2010-08-24 |
ES2184769T3 (es) | 2003-04-16 |
WO1995011010A1 (en) | 1995-04-27 |
EP0724432B1 (de) | 2002-09-18 |
DE69431404T2 (de) | 2003-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE224184T1 (de) | Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe | |
DE69431358T2 (de) | Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien | |
DE3768833D1 (de) | Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren. | |
ATE466869T1 (de) | Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden | |
DE68918142T2 (de) | Zusammensetzungen und Verfahren zur kontrollierten Freisetzung von Duftstoffen. | |
BR9809656A (pt) | Composição imunopotencializante | |
DK1042001T3 (da) | Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner | |
DE69231837T2 (de) | Antigen praesentierende ms2-huelle | |
ITMI920168A0 (it) | Sistemja e metodo per controllare le vibrazioni sincrone di palette | |
DE3486160T2 (de) | Modifizierte lebende Pseudo-Rabies-Viren, diese enthaltende Impfstoffe gegen Pseudo-Rabies, Verfahren zur Herstellung und Verfahren zur Verwendung derselben. | |
DK0585943T3 (da) | Opløselige ligander for CD40 | |
DE60004496D1 (de) | Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff | |
ATE249840T1 (de) | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung | |
DK0851927T3 (da) | Forbindelser til immunterapi og diagnosticering af tuberkulose | |
DK0885244T3 (da) | Peptidimmunogener til vaccination imod og til behandling af allergi | |
DK0668772T3 (da) | Specifik immunsystemmodulering | |
DE59001862D1 (de) | Verfahren und mahlanlage zur zweistufigen zerkleinerung von sproedem mahlgut. | |
ATE101876T1 (de) | Verfahren zur verringerung der heterogenitaet von monoklonalen antikoerpern. | |
ATE416787T1 (de) | Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien | |
IL139601A0 (en) | Compositions and methods of modulating an immune response to an antigen | |
ATE72400T1 (de) | Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen. | |
DK0728015T3 (da) | Kombinatoriske polypeptidantigener | |
MX9203574A (es) | Metodo biotecnologico para la produccion de peptidos antigenicos relacionados con el antigeno p asociado al melanoma, y para preparar vacunas que los contienen. | |
ATE152916T1 (de) | Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind | |
DK0542895T3 (da) | Krydsreaktiv influenza A immunisering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |